Smart Animal is taking an innovative approach to bring the world of immunotherapy and diagnostics together. We recognize that the body has the innate ability to target a response to almost every invading pathogen or biological aberration that it encounters. Natural defenses succeed in defeating over 99% of these conditions using the most sophisticated array of tools known to mankind, including the adaptive immune response. And for cases where these responses are not enough, Smart Animal is there to help the patient help themselves, by temporarily modifying or enhancing these responses to bring this success rate back to 100% again. The treatment is as individual as the patient, but can be administered in an out-patient or clinic setting by trained technicians or nursing staff. It utilizes an innovative platform-oriented device for which Smart Animal has secured patents in the United States and in Australia, with additional patents pending in the US and Canada. For cancer applications, this technology will be used to label a specific subset of a patient’s own antibodies with an imaging tag over a span of just hours. Later, whole-body imaging is used to visualize the distribution of the label in the patient and to determine if the immune system is recognizing it's own disease state, including sites of metastasis. The effectiveness of the labeling and targeting to the sites of interest can be measured. This same device can also be used to target a therapeutic compound to the imaged sites resulting in a quantitative drug delivery method with improved pharmacological properties. The device can be applied to other diseases, such as autoimmune disorders. Also for veterinary use. SAI is in the process of seeking early-stage funding to manufacture advanced prototypes, to screen canine and human cancer models, and to pursue promising candidates in animal models. Interested investors can find out more by contacting the founder, Gary McNeil, here on LinkedIn.